New insider activity at Abbott Laboratories ( (ABT) ) has taken place on May 3, 2025.
Director Sally Blount has recently sold 2,600 shares of Abbott Laboratories stock, amounting to a total transaction value of $337,116.
Recent Updates on ABT stock
Abbott Laboratories recently held its Q1 earnings call, revealing strong financial performance with significant growth in its medical devices and nutrition segments. The company reported a 7% increase in sales, excluding COVID testing, and an 11% rise in adjusted earnings per share. Despite facing challenges from tariffs and a decline in diagnostics sales, particularly in China, Abbott’s strategic investments and product innovations are seen as a solid foundation for future growth. The company is making substantial investments in manufacturing and R&D, aiming to expand its US transfusion diagnostic business. Abbott reaffirmed its full-year guidance, projecting continued growth driven by its diversified business model and strategic initiatives. Analysts have raised the company’s price target, reflecting confidence in its ability to navigate market uncertainties and sustain growth.
Spark’s Take on ABT Stock
According to Spark, TipRanks’ AI Analyst, ABT is a Outperform.
Abbott Laboratories shows strong financial performance, particularly in revenue and profit growth, and has strategic initiatives for future expansion. While the technical indicators are mixed, the company’s fair valuation and positive earnings call highlight its resilience and potential for growth. However, attention to leverage and external challenges such as tariffs is necessary.
To see Spark’s full report on ABT stock, click here.
More about Abbott Laboratories
YTD Price Performance: 16.86%
Average Trading Volume: 7,089,042
Technical Sentiment Signal: Sell
Current Market Cap: $227.7B